CRL
$232.01
Charles River Laboratories Intl
($.53)
(.23%)
CRL
Earnings Whisper ®
N/A
4th Quarter December 2020
Consensus:  $2.11
Revenue:  $745.48 Mil
Thursday
Jan 28
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CRL reports earnings?
Beat
Meet
Miss

Where is CRL's stock price going from here?
Up
Flat
Down
Stock chart of CRL
Analysts
Summary of analysts' recommendations for CRL
Score
Grade
Pivots
Resistance
$239.34
$237.54
$235.04

$233.24

Support
$230.74
$228.94
$226.44
Tweet
Growth
Description
Charles River Laboratories International, Inc. provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Their dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. At Charles River, they are passionate about their role in improving the quality of people's lives. Their mission, their excellent science and strong sense of purpose guide in all that they do, and they approach each day with the knowledge that their work helps to improve the health and well-being of many across the globe. Charles River Laboratories International, Inc. service areas are Basic research, discovery, safety and efficacy, clinical support and manufacturing.
Peers
Alexion PharmaceuticalsExact SciencesIncyteExelixisCoherus BiosciencesLuminex